MX2015005805A - Derivados de bendamustina y métodos para utilizarlos. - Google Patents
Derivados de bendamustina y métodos para utilizarlos.Info
- Publication number
- MX2015005805A MX2015005805A MX2015005805A MX2015005805A MX2015005805A MX 2015005805 A MX2015005805 A MX 2015005805A MX 2015005805 A MX2015005805 A MX 2015005805A MX 2015005805 A MX2015005805 A MX 2015005805A MX 2015005805 A MX2015005805 A MX 2015005805A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- bendamustine
- bendamustine derivatives
- derivatives
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical class ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229960002707 bendamustine Drugs 0.000 abstract 1
- -1 bendamustine amides Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725213P | 2012-11-12 | 2012-11-12 | |
| US201361776951P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/069550 WO2014075035A1 (en) | 2012-11-12 | 2013-11-12 | Bendamustine derivatives and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005805A true MX2015005805A (es) | 2016-04-15 |
Family
ID=49667594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005805A MX2015005805A (es) | 2012-11-12 | 2013-11-12 | Derivados de bendamustina y métodos para utilizarlos. |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US9452988B2 (OSRAM) |
| EP (1) | EP2917183A1 (OSRAM) |
| JP (1) | JP6262246B2 (OSRAM) |
| KR (1) | KR20150086308A (OSRAM) |
| AR (1) | AR093457A1 (OSRAM) |
| AU (1) | AU2013342015B2 (OSRAM) |
| BR (1) | BR112015010501A2 (OSRAM) |
| CA (1) | CA2890462A1 (OSRAM) |
| CL (1) | CL2015001246A1 (OSRAM) |
| EA (1) | EA029706B1 (OSRAM) |
| HK (2) | HK1215701A1 (OSRAM) |
| IL (1) | IL238662A (OSRAM) |
| MX (1) | MX2015005805A (OSRAM) |
| PH (1) | PH12015501024A1 (OSRAM) |
| SG (1) | SG11201503560TA (OSRAM) |
| TW (1) | TWI598341B (OSRAM) |
| WO (1) | WO2014075035A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693720B (zh) | 2010-05-20 | 2019-01-18 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| MX2015005805A (es) * | 2012-11-12 | 2016-04-15 | Ignyta Inc | Derivados de bendamustina y métodos para utilizarlos. |
| CA2904143A1 (en) * | 2013-03-12 | 2014-10-09 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
| EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| WO2018013783A1 (en) * | 2016-07-13 | 2018-01-18 | Cephalon, Inc. | Pharmaceutical prodrugs and methods of their preparation and use |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681964A (en) * | 1990-10-23 | 1997-10-28 | University Of Kentucky Research Foundation | Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US7089218B1 (en) | 2004-01-06 | 2006-08-08 | Neuric Technologies, Llc | Method for inclusion of psychological temperament in an electronic emulation of the human brain |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| WO2002043663A2 (en) | 2000-12-01 | 2002-06-06 | Enzon, Inc. | Tetrapartate prodrugs |
| WO2003086369A2 (en) * | 2002-04-05 | 2003-10-23 | Valorisation-Recherche, Societe En Commandite | Stealthy polymeric biodegradable nanospheres and uses thereof |
| EP2359859A1 (en) | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CA2598239C (en) | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
| EP2222278B1 (en) | 2007-11-28 | 2015-04-08 | Celator Pharmaceuticals, Inc. | Improved taxane delivery system |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| JP5670335B2 (ja) * | 2008-09-25 | 2015-02-18 | セファロン、インク． | ベンダムスチン液体製剤 |
| WO2010037142A1 (en) * | 2008-09-29 | 2010-04-01 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| JP5773874B2 (ja) * | 2008-10-08 | 2015-09-02 | セファロン、インク． | ベンダムスチンの調製方法 |
| CN105363037B (zh) * | 2008-12-03 | 2019-02-05 | 安斯泰来德国有限公司 | 苯达莫司汀的口服剂型 |
| BR112012030654B1 (pt) | 2010-06-02 | 2021-11-09 | Astellas Deutschland Gmbh | Composição farmacêutica para administração oral compreendendo bendamustina ou um sal farmaceuticamente aceitável da mesma, como um ingrediente ativo, e um excipiente farmaceuticamente aceitável |
| TWI455722B (zh) | 2010-06-04 | 2014-10-11 | Pfizer Vaccines Llc | 用於預防或治療菸鹼成癮之共軛體 |
| CN101966158A (zh) | 2010-09-28 | 2011-02-09 | 上海丽思化工科技有限公司 | 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法 |
| EP2635558A4 (en) | 2010-11-01 | 2014-08-06 | Shilpa Medicare Ltd | PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE |
| DE102010055499A1 (de) | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| US9308276B2 (en) | 2011-05-17 | 2016-04-12 | University Of South Alabama | Combination therapy for treatment of cancer |
| ES2613838T3 (es) | 2011-09-26 | 2017-05-26 | Fresenius Kabi Oncology Ltd | Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina |
| PT2656843E (pt) | 2012-04-26 | 2015-04-14 | Helmut Schickaneder | Ésteres de bendamustina e compostos relacionados e a sua utilização médica |
| US10526290B2 (en) | 2012-06-19 | 2020-01-07 | Synbias Pharma Ag | Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy |
| JP2015525799A (ja) | 2012-08-10 | 2015-09-07 | ユニバーシティ・オブ・ノース・テキサス・ヘルス・サイエンス・センターＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ | ターゲティングポリアミノ酸および脂肪酸のコンジュゲートを含む薬物送達ビークル |
| MX2015005805A (es) * | 2012-11-12 | 2016-04-15 | Ignyta Inc | Derivados de bendamustina y métodos para utilizarlos. |
-
2013
- 2013-11-12 MX MX2015005805A patent/MX2015005805A/es unknown
- 2013-11-12 KR KR1020157015682A patent/KR20150086308A/ko not_active Withdrawn
- 2013-11-12 SG SG11201503560TA patent/SG11201503560TA/en unknown
- 2013-11-12 US US14/442,088 patent/US9452988B2/en not_active Expired - Fee Related
- 2013-11-12 EA EA201590925A patent/EA029706B1/ru not_active IP Right Cessation
- 2013-11-12 WO PCT/US2013/069550 patent/WO2014075035A1/en not_active Ceased
- 2013-11-12 HK HK16100090.1A patent/HK1215701A1/zh unknown
- 2013-11-12 EP EP13795940.9A patent/EP2917183A1/en not_active Withdrawn
- 2013-11-12 BR BR112015010501A patent/BR112015010501A2/pt not_active IP Right Cessation
- 2013-11-12 JP JP2015541995A patent/JP6262246B2/ja not_active Expired - Fee Related
- 2013-11-12 CA CA2890462A patent/CA2890462A1/en not_active Abandoned
- 2013-11-12 TW TW102140964A patent/TWI598341B/zh not_active IP Right Cessation
- 2013-11-12 AU AU2013342015A patent/AU2013342015B2/en not_active Ceased
- 2013-11-12 AR ARP130104160A patent/AR093457A1/es unknown
- 2013-11-12 HK HK16100891.2A patent/HK1212977A1/zh unknown
-
2015
- 2015-04-29 US US14/699,965 patent/US9150517B2/en not_active Expired - Fee Related
- 2015-05-06 IL IL238662A patent/IL238662A/en not_active IP Right Cessation
- 2015-05-07 PH PH12015501024A patent/PH12015501024A1/en unknown
- 2015-05-08 CL CL2015001246A patent/CL2015001246A1/es unknown
- 2015-05-13 US US14/711,747 patent/US9149464B2/en not_active Expired - Fee Related
- 2015-09-28 US US14/868,278 patent/US20160016912A1/en not_active Abandoned
-
2016
- 2016-06-16 US US15/184,968 patent/US9630926B2/en not_active Expired - Fee Related
-
2017
- 2017-03-10 US US15/456,439 patent/US9913827B2/en not_active Expired - Fee Related
-
2018
- 2018-01-24 US US15/879,130 patent/US20180147186A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501024A1 (en) | Bendamustine derivatives and methods of using same | |
| PH12019501197A1 (en) | Therapeutically active compounds and their methods of use | |
| IN2014MN02652A (OSRAM) | ||
| IN2014MN02598A (OSRAM) | ||
| IN2014MN02657A (OSRAM) | ||
| PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
| TN2015000380A1 (en) | Heterocyclic compounds and their uses | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2015DN01156A (OSRAM) | ||
| IN2014MN02658A (OSRAM) | ||
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| MY174188A (en) | Heterocyclyl compounds | |
| IN2015DN01119A (OSRAM) | ||
| GB201209587D0 (en) | Therapeutic compounds | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| MD20170011A2 (ro) | Compuşi imidazopiridazinici | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| MX2013005819A (es) | Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. | |
| PH12015500399A1 (en) | Azaindolines | |
| MX2013014398A (es) | Derivados de sulfonamida heterociclicos. | |
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
| MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| IN2013MU02813A (OSRAM) | ||
| IN2013CH03945A (OSRAM) |